1st production QuiremSpheres
On May 21st, the first patient dosis of QuiremSpheres was processed at RTM and then shipped to the stituto Nazionale dei Tumori hospital in Milan, Italy. There it was used for the treatment of a patient suffering from hepatocellular carcinoma (HCC). QuiremSpheres® are radioactive microspheres for SIRT and are based on the isotope holmium-166.
Voor meer informatie: http://www.quirem.com/

Other news

RTM receives marketing authorisation for Fludeoxyglucose (18F)
We are happy to announce that RTM has received marketing authorization for 18F-FDG of 17 July 2018....
ABX has received marketing authorisation for the radiotracer Radelumin® in Germany
ABX has received marketing authorisation for the radiotracer Radelumin® in Germany! This marks the 8...

LinkedIn post Isologic goes electric
🔌Isologic Goes Electric! We are excited to announce the expansion of our electric fleet with the a...

First liver cancer patient treated with microspheres irradiated in TU Delft
Radboud Translational Medicine will perform the dispensing of below product. The production and dis...
Interested in a collaboration?
Contact us to discuss the possibilities.